Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | AQP1 | P29972 | 1/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | CISD1 | Q9NZ45 | 7/20 | 0.47 |
| ▸ | CA1 | P00915 | 6/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA3 | P07451 | 4/20 | 0.42 |
| ▸ | CA6 | P23280 | 4/20 | 0.42 |
| ▸ | CA5A | P35218 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2741842 | 0.92 | CA2 (0.66) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL16581178 | 0.89 | CA2 (0.53) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL11853823 | 0.87 | HPGD (0.54) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL11780993 | 0.84 | CA2 (0.56) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL11783535 | 0.84 | CA2 (0.58) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL16581037 | 0.82 | CA2 (0.58) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL2742069 | 0.80 | KDM4E (0.86) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL16581252 | 0.80 | CA2 (0.55) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL16581064 | 0.78 | CISD1 (0.56) | CA2HPGDKDM4EUSP2ALDH1A1 | |
| SCHEMBL16581179 | 0.78 | CA2 (0.52) | CA2HPGDKDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | CA2 1422/4885HPGD 1748/4885KDM4E 3717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.